Scholars Central

Mini reviewPublished 29 Dec 2022

Interfere with the ability Therapeutic Innovations and developments

Authors: Andramarina Smith

Journal of Clinical Endocrinology Research

Volume 5 · Issue 6 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A significant contributor to thyroid problems and infertile, protactinium make up around 40% of all benign tumours. The rehabilitation or attainment of eugonadism through the normalisation of amenorrhea and management of tumour bulk is the overarching goal of treatment for prolactinomas. Most of the time, medical therapy with dopamine agonists is quite successful and serves as the cornerstone of treatment. The notion that medical therapy is a lifetime necessity is challenged by recent findings showing effective removal of these drugs in a subset of people. Pregnancies, huge or cancerous prolactinomas, resistance to dopamine agonists, and many other complex conditions may call for process of management major surgery, radiation, or even both.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical Endocrinology Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Endocrinology Research
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Andramarina Smith”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels